Buprenorphine Treatment Guidelines

Introduction to Treatment Phases

• Patients require weekly visits during the initial/titration phase, which typically lasts 2-4 weeks, for dose adjustment and telephone contact, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 2.
• The initial/titration phase duration and visit frequency are crucial for effective treatment and minimizing risks 1, 2.

Maintenance Phase Guidelines

• The minimum standard for stable patients on buprenorphine during the maintenance phase is monthly visits, with potential reduction to every 3-6 months for highly stable patients with good treatment response and low risk for relapse or diversion, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 2.
• Psychosocial support is essential during the maintenance phase to address stressors and adherence issues, providing an opportunity for ongoing patient care and support 1.

Discontinuation Phase Guidelines

• More frequent monitoring is required during the discontinuation phase compared to the maintenance phase to identify withdrawal symptoms or early relapse, emphasizing the need for close patient supervision 1.
• Close monitoring during dose tapering is necessary to minimize risks and ensure patient safety 1.

Special Considerations

• Patients with unstable housing, social support, or psychiatric disorders, as well as those with a history of medication non-adherence or recent relapse, may require more frequent visits, as recommended by the American Academy of Child and Adolescent Psychiatry 1.
• The American Academy of Child and Adolescent Psychiatry and the American Medical Association guidelines recommend caution with the combination of buprenorphine and benzodiazepines due to the risk of respiratory depression, sedation, and potential fatal outcomes 3.
• Alternative anxiolytics, such as buspirone, SSRIs, trazodone, and gabapentin, are recommended as first-line treatments instead of benzodiazepines, according to the Mayo Clinic Proceedings 3.
• A tapering plan for benzodiazepines, with gradual dose reduction and monitoring for withdrawal symptoms, is recommended to minimize risks, as suggested by the Mayo Clinic Proceedings 3.
• Non-opioid analgesics should be maximized first for pain management, and adjunctive non-opioid therapies can enhance pain management, as recommended by the American Academy of Pain Medicine 4.
• Individualized treatment is necessary for perioperative pain management in patients on buprenorphine, considering the prescribed daily dose, indication for treatment, risk of relapse, and expected level of postsurgical pain, as recommended by the Mayo Clinic Proceedings 5.
• Concomitant use of buprenorphine with QT-prolonging agents should be avoided, according to the Mayo Clinic Proceedings 5.

3